Knight Therapeutics Inc T.GUD

Alternate Symbol(s): KHTRF

Healthcare Biotechnology

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.

TSX:GUD - Post by User

Knight Therapeutics Inc

Bullboard Posts

Comment by JohnnyUtah16on Jul 18, 2019 3:54pm

59 Views

Post# 29936505

RE:RE:Funny

If any of you are seriously suggesting shareholders side with Meir over JG (again), give your head a shake and think harder. Because there is zero logic that would ever give you a good reason to chose Meir in this situation. Don't listen to all the bs, use your head and listen to the facts. No brainer.

Bullboard Posts

Quantum eMotion leaps by 20 per cent after Becton Dickinson deal